Table of Contents
Chapter 1. Research Methodology
1.1. Report Scope
1.2. List of Secondary Sources
1.3. List of Abbreviations
Chapter 2. Executive Summary
2.1. Oncology Clinical Trials Landscape Overview
2.2. Market Dynamics
2.3. Prevalence Trends Analysis
2.3.1. Breast Cancer
2.3.2. Non-small cell lung cancer (NSCLC)
2.3.3. Prostate Cancer
2.3.4. Colorectal Cancer
2.3.5. Melanoma
2.3.6. Bladder Cancer
2.3.7. Leukemia and Lymphoma
2.3.8. Others
2.4. R&D Investment & Funding Analysis
2.5. Pricing Analysis
2.6. Industry Ecosystem Analysis
2.7. Regulatory Framework
2.8. List of Top 100 Active Trials by Phase, Sponsor, and Indication
2.9. Emerging Clinical Trial Design Analysis
Chapter 3. Global Oncology Clinical Trials, by Phase
3.1. Phase I
3.2. Phase II
3.3. Phase III
3.4. Phase IV
Chapter 4. Global Oncology Clinical Trials, by Study Design
4.1. Interventional Trials
4.2. Observational Studies
4.3. Expanded Access
Chapter 5. Global Oncology Clinical Trials, by Key Indications
5.1. Breast Cancer
5.2. Non-small cell lung cancer (NSCLC)
5.3. Prostate Cancer
5.4. Colorectal Cancer
5.5. Melanoma
5.6. Bladder Cancer
5.7. Leukemia and Lymphoma
5.8. Others
Chapter 6. Global Oncology Clinical Trials, by Region
6.1. North America
6.2. Europe
6.3. Asia Pacific
6.4. Latin America
6.5. Middle East & Africa